Back to results
US 2017/0050924 A1Published application
Inhibitors of creatine transport and uses thereof
AssigneeRgenix, Inc.
InventorsEduardo J. MARTINEZ, Sohail F. TAVAZONE
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
Claims74
A compound having the structure:
- wherein Q1 is optionally substituted amidino;
- m is 1 or 2;
- R7 is hydrogen, optionally substituted C1-C6 alkyl, or optionally substituted C6-C10 aryl C1-C6 alkyl;
- R8 and R9 are independently hydrogen, deuterium, halo, hydroxyl, NH2, optionally substituted C1-C3 alkyl, or R8 and R9 combine with the atoms to which they are attached to form an optionally substituted C3-C6 cycloalkyl ring;
- or R8 or R9 combine with R10 or R11 with the atoms to which they are attached to form an optionally substituted C3-C4 cycloalkyl ring;
- or R8 or R9 combine with R12 with the atoms to which they are attached to form an optionally substituted C3-C5 heterocycle;
- R10 and R11 are independently hydrogen, deuterium, optionally substituted C1-C4 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl or R10 and R11 combine with the atoms to which they are attached to form an optionally substituted C3-C6 cycloalkyl ring;
- or R10 or R11 combine with R8 or R9 with the atoms to which they are attached to form an optionally substituted C3-C4 cycloalkyl ring;
- or R10 or R11 combine with R12 with the atoms to which they are attached to form an optionally substituted C3-C4 heterocycle;
- R12 is hydrogen, optionally substituted C1-C6 alkyl, or R12 combines with R8 or R9 with the atoms to which they are attached to form an optionally substituted C3-C5 heterocycle, or R12 combines with R10 or R11 with the atoms to which they are attached to form an optionally substituted C3-C4 heterocycle
- wherein if m is 1 and R8 is hydrogen, halo, hydroxyl, or methyl then at least one of R9, R10, and R11 is not hydrogen;
- wherein if m is 1 and R10 is methyl then at least one of R8, R9, and R11 is not hydrogen;
- wherein if m is 1 and R8 is NH2 and R10 is hydrogen, methyl, or —CH2CH2OH then at least one of R9 or R11 is not hydrogen;
- wherein if m is 1, R8 is halo, and R10 is optionally substituted C1-C4 alkyl then at least one of R9 and R10 is not hydrogen;
- or a pharmaceutically acceptable salt thereof.
12 more elements
The compound of claim 45 or 46, wherein said compound has the structure of Formula IX:
A compound selected from any one of compounds 253-262 and 327-385 in Table 4.
A compound selected from any one of compounds 258, 327-338, 340, 343-348, 351-352, 366-367, 369-370, 372-375, and 379-385 in Table 4.
Dependencies are inferred from the claim text.